[ADMS] Adamas Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 17.42 Change: 0.78 (4.69%)
Ext. hours: Change: 0 (0%)

chart ADMS

Refresh chart

Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Fundamental Ratios
Shares Outstanding EPS-2.84 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -99.1% Sales Growth - Q/Q-99.25% P/E-6.16
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA2.99% ROE3.2% ROI
Current Ratio14.25 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin21.43% Net Profit Margin7.87% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-18.45 M Cash From Operating Activities-14.06 M Gross Profit
Net Profit-12.2 M Operating Profit-12.23 M Total Assets147.34 M Total Current Assets115.52 M
Total Current Liabilities8.11 M Total Debt Total Liabilities9.79 M Total Revenue230 K
Technical Data
High 52 week42.65 Low 52 week5.48 Last close5.73 Last change-3.86%
RSI31.77 Average true range0.3 Beta1.57 Volume92.31 K
Simple moving average 20 days-5.84% Simple moving average 50 days-15.11% Simple moving average 200 days-74%
Performance Data
Performance Week2.32% Performance Month-10.47% Performance Quart-76.34% Performance Half-81.62%
Performance Year-79.54% Performance Year-to-date-75.52% Volatility daily2.42% Volatility weekly5.41%
Volatility monthly11.1% Volatility yearly38.44% Relative Volume208.74% Average Volume562.75 K
New High New Low

News

2020-06-05 07:34:09 | The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid

2020-06-04 16:30:10 | Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

2020-06-03 16:01:10 | Adamas to Present at Upcoming William Blair Conference

2020-05-13 09:15:10 | Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time

2020-05-08 18:46:23 | Adamas Announces New Employment Inducement Grant

2020-05-08 04:11:44 | Edited Transcript of ADMS earnings conference call or presentation 7-May-20 9:00pm GMT

2020-05-07 16:03:10 | Adamas Reports First Quarter 2020 Financial Results

2020-04-30 12:34:04 | Adamas Pharmaceuticals ADMS Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

2020-04-28 12:00:04 | All You Need to Know About Adamas ADMS Rating Upgrade to Buy

2020-04-27 16:03:10 | Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020

2020-04-10 16:06:10 | Adamas Announces New Employment Inducement Grant

2020-03-23 15:15:56 | Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors – ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

2020-03-20 10:44:02 | Generic Drugs Industry's Prospects Uncertain Amid Coronavirus

2020-03-19 16:46:00 | Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.

2020-03-07 09:56:26 | Edited Transcript of ADMS earnings conference call or presentation 25-Feb-20 9:30pm GMT

2020-03-06 16:39:18 | Adamas Announces New Employment Inducement Grant

2020-02-28 06:26:53 | Earnings Update: Here's Why Analysts Just Lifted Their Adamas Pharmaceuticals, Inc. Price Target To US$12.69

2020-02-25 17:35:10 | Adamas Pharmaceuticals ADMS Reports Q4 Loss, Tops Revenue Estimates

2020-02-25 16:03:10 | Adamas Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-24 09:02:02 | Cronos CRON to Report Q4 Earnings: What's in the Cards?

2020-02-20 16:01:10 | Adamas to Present at Upcoming Healthcare Conferences

2020-02-19 16:02:10 | Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020

2020-02-13 09:00:10 | Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

2020-02-12 09:18:32 | The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

2020-02-11 16:15:10 | Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease

2020-02-10 10:50:00 | SHAREHOLDER ALERT: ADMS GDOT BYND: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2020-02-10 10:00:33 | ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS

2020-02-10 09:57:00 | FINAL DEADLINE ALERT - Adamas Pharmaceuticals, Inc. ADMS - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

2020-02-09 10:25:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, OPRA and PTLA

2020-02-08 10:30:00 | ADMS FINAL DEADLINE: ROSEN, INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10 Deadline in Securities Class Action - ADMS

2020-02-07 13:30:00 | CLASS ACTION UPDATE for ADMS, GDOT and PTLA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2020-02-07 10:00:10 | DEADLINE ALERT - Adamas Pharmaceuticals, Inc. ADMS - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

2020-02-06 17:40:00 | CLASS ACTION UPDATE for ADMS, SSL and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2020-02-06 13:30:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2020-02-05 18:00:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, GDOT and FSCT

2020-02-05 15:15:00 | 5-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2020-02-05 13:40:00 | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, XYF and PTLA

2020-02-05 11:26:10 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

2020-02-05 10:52:00 | CLASS ACTION UPDATE for ADMS, FSCT and BYND: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2020-02-05 09:56:00 | DEADLINE ALERT - Adamas Pharmaceuticals, Inc. ADMS - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

2020-02-04 20:40:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, FSCT and PTLA

2020-02-04 20:05:00 | 6-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2020-02-04 13:41:07 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2020-02-04 12:30:00 | SHAREHOLDER ALERT: ADMS PTLA GERN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2020-02-04 12:00:10 | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.

2020-02-04 11:12:10 | INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines

2020-02-04 10:12:00 | ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc

2020-02-03 15:45:00 | SHAREHOLDER ALERT: ADMS GDOT PTLA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2020-02-03 13:45:00 | NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2020-02-03 13:00:10 | DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders